Expression of HER-2/neu Oncoprotein in Familial and Non-Familial Breast Cancer

HER-2/neu proto-oncogene的放大（amplification）或HER-2/neu oncoprotein的過度表現（overexpression），被認為是影響乳癌患者治療反應及預後的重要因素，同時也是提供是否使用Herceptin（Trastuzumab）治療的依據。以往的研究統計顯示，一般乳癌患者的HER-2/neu oncoprotein過度表現的比率約佔10%－40%，　家族性乳癌的HER-2/neu oncoprotein的表現率，是否比一般或非家族性的表現率高，是值得探討的主題。本文蒐集自一九九○到一九九九之間，56例家族性乳癌及111例非家族性乳癌，使用組織化學免疫染色來比較HER-2/neu oncoprotein過度表現的差異，並與腫瘤的組織型態、分級及分期作相關性的分析，結果顯示家族性乳癌整體的HER-2/neu oncoprotein表現陽性率比非家族性乳癌高，分別為50%及36.9%，兩者在統計上沒有意義（P=0.1068），但如果針對浸潤性對癌（infiltrating ductal carcinoma）作比較，分別為52.3%和33.7%，兩者則有差異（P=0.0429）。在非家族性及整體的乳癌病例，HER-2/neu oncoprotein表現陽性率和侵襲性腺管癌組織形態的分級（histological grade）與淋巴結的轉移相關，而組織形態中和細胞分裂（mitotic counts）及細胞核的多形性（nuclear pleomorphism）有關，但與小管腔的形成（tubule formation）不相關。３例Paget’s disease的HER-2/neu oncoprotein的表現都呈陽性，而12例黏液腺癌（mucinous carcinoma），1例髓樣癌（medullary carcinoma）及1例化生癌（metaplastic carcinoma）則都呈陰性。腺管內癌（intraductal carcinoma）的HER-2/neu oncoprotein表現陽性率在兩組都很高，分別為57.1%和73.3%，兩者在統計上沒有差異（P=0.4716），在1例伴有浸潤性腺管癌及腺管內癌的腫瘤，出現浸潤性癌細胞呈陰性的HER-2/neu oncoprotein染色，而腺管內癌細胞呈現較強的非均質染色，顯示部份腺管內癌在進展到侵襲性腺管癌時，其HER-2/neu oncoprotein的表現在腺管內癌，Paget’s disease和侵襲性乳癌可能具有不同的意義，所以在統計乳癌的HER-2/neu oncoprotein過度表現率時，應依腫瘤病理組織形態類別分開作統計及比較。

關鍵字

無資料

並列摘要

The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a-predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. Moreover, it is an entry criterion in the assessment of patients for whom Herceptin (Trastuzumab) treatment is considered. The overexpression rate of HER-2/nue oncoprotein has been identified in 10% to 40% of human breast cancers. In Taiwan, a higher grade of pathobiologic characteristics of familial breast cancer was also noted than that found in the non-familial group. It is worthwhile to evaluate whether the overexpression is more frequent in familial breast cancers. Fifty-six familial and 111 non-familial breast cancers were studied between 1990 and 1999 to assess both the overexpression of HER-2/neu oncoprotein immunohistochemically and the correlation with the histological type, grade and stage of breast carcinoma. The overexpression rate is higher in the familial breast cancer group (50.0%) when compared with non-familial breast cancer group (36.9%), which did not prove to be statistically significant (P=0.1068). However, when the infiltrating ductal carcinomas of both groups are compared, it is statistically significant (52.3% vs. 33.7%, P=0.0429). Overexpression correlated with node status and histological grade of infiltrating ductal carcinomas in non-familial and overall breast cancers. It also correlated with nuclear pleomorphism and mitotic counts, but not tubule formation or tumor size. All 3 cases of Paget’s disease revealed overexpression, whereas all 12 cases of mucinous and one case of metaplastic carcinoma and one case of medullary carcinoma were negative. The overexpression rate was higher both in familial and non-familial intraductal carcinomas (57.1% vs. 73.3%, P=0.4716). No statistical difference was identified between the 2 subsets. A case of infiltrating ductal carcinoma combined with intraductal carcinoma revealed hetereogeneous staining in the component of ductal carcinoma in situ, while the invasive component did not. This suggests that overexpression decreases within individual tumors as they evolve from in situ to invasive lesioins. The HER-2/neu may imply a different role in intraductal carcinoma, Paget’s disease and invasive duct carcinoma. Although the overexpression rate of HER-2/neu oncoprotein of familial breast cancer was not significantly higher than that of the non-familial group, it is appropriate to evaluate the rate of HER-2/neu overexpression according to the histological type of breast cancers from familial breast cancer and non-familial breast cancer. The prognoses will be needed for future evaluation.

並列關鍵字

familial breast cancer ； HER-2/neu oncoprotein ； immunohistochemistry

國際替代計量

Expression of HER-2/neu Oncoprotein in Familial and Non-Familial Breast Cancer

全文下載

主題瀏覽